Raymond James Financial Inc. Purchases 4,571 Shares of CRISPR Therapeutics AG $CRSP

Raymond James Financial Inc. increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,666 shares of the company’s stock after purchasing an additional 4,571 shares during the period. Raymond James Financial Inc. owned 0.10% of CRISPR Therapeutics worth $2,949,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Costello Asset Management INC bought a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at $27,000. Wood Tarver Financial Group LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $30,000. Ameriflex Group Inc. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $36,000. NBC Securities Inc. raised its position in shares of CRISPR Therapeutics by 156,300.0% during the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company’s stock valued at $53,000 after purchasing an additional 1,563 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $71,000. 69.20% of the stock is currently owned by institutional investors.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George acquired 989,812 shares of the company’s stock in a transaction on Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the purchase, the director directly owned 1,730,179 shares of the company’s stock, valued at approximately $90,021,213.37. This represents a 133.69% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Stock Up 4.0%

Shares of NASDAQ:CRSP opened at $54.86 on Monday. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The stock has a market capitalization of $4.99 billion, a P/E ratio of -10.10 and a beta of 1.81. The firm has a fifty day simple moving average of $56.36 and a two-hundred day simple moving average of $45.43.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $6.44 million. During the same period last year, the company posted ($1.49) EPS. The business’s revenue was up 72.5% on a year-over-year basis. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wall Street Zen upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, May 16th. Chardan Capital reiterated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Bank of America reduced their price target on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Royal Bank Of Canada lifted their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a report on Tuesday, August 5th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $71.60.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.